Associations of Serum Adiponectin and Leptin With Barrett's Esophagus

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2265-2272

  Greer, Katarina B ^a   Falk, Gary W ^b   Bednarchik, Beth ^a   Li, Li ^a   Chak, Amitabh ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adipokine; Epidemiology; Esophagus

Indexed keywords

ADIPONECTIN; LEPTIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CASE CONTROL STUDY; COLONOSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RACE; SEX DIFFERENCE; WAIST HIP RATIO; AGED; BLOOD; CHEMISTRY; MIDDLE AGED; PATHOLOGY; SERUM;

ADIPONECTIN; ADULT; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; SERUM; SEX FACTORS;

EID: 84947488652     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.02.037     Document Type: Article

References (26)

1. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
2. Pohl H., Sirovich B., Welch H.G. Esophageal adenocarcinoma incidence: are we reaching the peak?. Cancer Epidemiol Biomarkers Prev 2010, 19:1468-1470.
3. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
4. Cook M.B., Greenwood D.C., Hardie L.J., et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol 2008, 103:292-300.
5. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
6. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
7. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001, 50:443-459.
8. Clemons N., Phillips W., Lord R.V. Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastresophageal junction. Cancer Biol Ther 2013, 14:782-795.
9. Banks A.S., Davis S.M., Bates S.H., et al. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000, 275:14563-14572.
10. Bates S.H., Stearns W.H., Dundon T.A., et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003, 421:856-859.
11. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
12. Yamauchi T., Nio Y., Maki T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
13. Diez J.J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148:293-300.
14. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238 e3.
15. Francois F., Rope J., Goodman A.J., et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008, 57:16-24.
16. Rubenstein J.H., Kao J.Y., Madanick R.D., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
17. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 2010, 18:2204-2211.
18. Greer K.B., Kresak A., Bednarchik B., et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut 2012, 61:665-672.
19. Mokrowiecka A., Daniel P., Jasinska A., et al. Serum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett's esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD. Hepatogastroenterology 2012, 59:2395-2399.
20. Ryan A.M., Healy L.A., Power D.G., et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008, 247:909-915.
21. Rubenstein J.H., Dahlkemper A., Kao J.Y., et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
22. Konturek P.C., Burnat G., Rau T., et al. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008, 53:597-605.
23. Beales I.L., Garcia-Morales C., Ogunwobi O.O., et al. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol 2014, 382:150-158.
24. Mokrowiecka A., Sokolowska M., Luczak E., et al. Adiponectin and leptin receptors expression in Barrett's esophagus and normal squamous epithelium in relation to central obesity status. J Physiol Pharmacol 2013, 64:193-199.
25. Rubenstein J.H., Morgenstern H., McConnel D., et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology 2013, 145:1237-1244. e1-5.
26. Ward E.M., Wolfsen H.C., Achem S.R., et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006, 101:12-17.